ReviewHNO2026
[Use of AI during creation of scientific reviews: the example of sarcopenia in head and neck cancer].
Review in HNO, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis article examines the impact of skeletal muscle mass and sarcopenia on the treatment of head and neck tumors using an AI-based review process and critically evaluates the Synthory.ai platform for systematic literature analysis. Articles from PubMed and PubMed Central published between January 2018 and March 2025 were included.
methodsAn automated review was generated via Synthory.ai using the query "role of sarcopenia in the treatment of head and neck cancer." The platform applies LLM-based (Large Language Model) relevance scoring for PubMed pre-selection. Only randomized controlled trials, cohort studies, and qualitative investigations with freely available full text were included. Of 146 screened articles, 26 were included and assessed using the Newcastle-Ottawa Scale and PRISMA criteria. One additional article (Jung et al.) was added through manual PubMed search.
resultsReduced skeletal muscle mass is associated with decreased overall survival (hazard ratio 1.36-4.51 in multivariate analyses) and increases the risk of dose-limiting toxicities during platinum-based chemoradiotherapy as well as postoperative complications. Studies applying comprehensive sarcopenia assessments (muscle mass, strength, and function) demonstrate stronger effect sizes. Studies differ substantially in terms of measurement methods and cut-off values.
conclusionReduced skeletal muscle mass is a negative prognostic marker in head and neck cancer patients; comprehensive sarcopenia assessment including muscle strength and function is substantially more predictive. Standardization of measurement methods and cut-off values is urgently needed. While AI-assisted review tools are valuable for literature analysis, they require expert validation and transparent documentation of selection processes.
Indexed as
Identifiers
42509365What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.